880-29-5

Usage

Uses

Used in Pharmaceutical Industry:
1-(4-Ethoxyphenyl)-2-thiourea is used as a reagent for the preparation of various pharmaceutical compounds, leveraging its unique chemical structure to facilitate the synthesis of new drugs.
Used in Organic Synthesis:
In the field of organic synthesis, 1-(4-Ethoxyphenyl)-2-thiourea serves as a key intermediate, contributing to the creation of complex organic molecules for a range of applications.
Used in Antifungal and Antibacterial Applications:
1-(4-Ethoxyphenyl)-2-thiourea is utilized for its potential antifungal and antibacterial properties, making it a candidate for the development of new drugs to combat infections.
Used in Cancer Treatment Research:
1-(4-ETHOXYPHENYL)-2-THIOUREA is studied for its potential applications in the treatment of cancer, due to its ability to inhibit certain enzymes and pathways involved in the disease, offering a new avenue for therapeutic intervention.
Used in Diabetes Treatment Research:
1-(4-Ethoxyphenyl)-2-thiourea is also being investigated for its potential role in diabetes treatment, as it may inhibit enzymes and pathways relevant to the disease, providing a novel approach to managing blood sugar levels.

InChI:InChI=1/C9H12N2OS/c1-2-12-8-5-3-7(4-6-8)11-9(10)13/h3-6H,2H2,1H3,(H3,10,11,13)

Upstream product

• 64289-08-3 1-(4-ethoxy-phenyl)-dithiobiuret 
• 156-43-4 4-Ethoxyaniline 
• 1147550-11-5 ammonium thiocyanate 
• 83697-75-0 N-(4-ethoxyphenyl)-N'-benzoylthiocarbamide 
• 3460-49-9 1-ethoxy-4-isothiocyanatobenzene 
• 333-20-0 potassium thioacyanate 

Downstream Products

• 102321-98-2 N-(4-ethoxy-phenyl)-N'-(4-diethylamino-phenyl)-thiourea 
• 73318-32-8 1-(4-Ethoxy-phenyl)-2-methyl-isothiourea; hydriodide 
• 472981-27-4 2-(4-ethoxyphenylamino)-4-(2-methyl-imidazo[1,2-a]pyrimidin-3-yl)thiazole monohydrobromide 
• 472980-97-5 2-(4-ethoxylphenyl)amino-4-(6-methylimidazo[2,1-b]thiazol-5-yl)thiazole monohydrobromide 
• 315703-52-7 N-(4-ethoxyphenyl)-4-(2-methylimidazo-[1,2-α] pyridine-3-yl)thiazol-2-amine 
• 150-69-6 N-(p-ethoxyphenyl)urea 
• 134420-06-7 p-ethoxy phenyl isonitrile 
• 134252-08-7 1-(4-Ethoxy-phenyl)-2-ethyl-isothiourea 
• 89606-97-3 (3aR,7aR)-1-(4-Ethoxy-phenyl)-4-ethyl-2-thioxo-2,3,3a,4,7,7a-hexahydro-1H-imidazo[4,5-b]pyrazine-5,6-dicarboxylic acid dimethyl ester 
• 97052-85-2 3-(4-Ethoxy-phenyl)-4-(4-fluoro-2-methyl-phenyl)-5-pentafluorophenylazo-3H-thiazol-2-ylideneamine 
• 97052-84-1 3-(4-Ethoxy-phenyl)-4-(4-fluoro-phenyl)-5-pentafluorophenylazo-3H-thiazol-2-ylideneamine 
• 116433-43-3 C₃₄H₃₆N₆O₆S₃ 
• 97105-69-6 4-(2-Chloro-4-fluoro-phenyl)-3-(4-ethoxy-phenyl)-5-phenylazo-3H-thiazol-2-ylideneamine 
• 97064-82-9 3-(4-ethoxyphenyl)-4-(4-fluoro-2-methylphenyl)-2-imino-5-phenylazothiazole 

Relevant academic research and scientific papers

Novel Piperine Derivatives with Antidiabetic Effect as PPAR-γ Agonists

Piperine is an alkaloid responsible for the pungency of black pepper. In this study, piperine isolated from Piper nigrum L. was hydrolyzed under basic condition to obtain piperic acid and was used as precursor to carry out the synthesis of twenty piperine derivatives containing benzothiazole moiety. All the benzothiazole derivatives were evaluated for their antidiabetic potential by OGT test followed by assessment of active derivatives on STZ-induced diabetic model. It was observed that nine of twenty novel piperine analogues (5b, 6a-h), showed significantly higher antidiabetic activity in comparison with rosiglitazone (standard). Furthermore, these active derivatives were evaluated for their action as PPAR-γ agonists demonstrating their mechanism of action. The effects on body weight, lipid peroxidation, and hepatotoxicity after administration with active derivatives were also studied to further establish these derivatives as lead molecules for treatment of diabetes with lesser side-effects.

Design and synthesis of N-Aryl isothioureas as a novel class of gastric H+/K+-ATPase inhibitors

To find new H+/K+-ATPase inhibitors for the treatment of peptic ulcer disease, a series of novel N-aryl isothiourea derivatives were synthesized and their structures were identified by 1H NMR and GC-MS. The effects of these compounds on inhibiting gastric acid secretion were evaluated by the guinea pig stomach mucous membrane study with pantoprazole magnesium as a positive control. The results showed that, of the 37 N-aryl isothiourea compounds synthesized, 20 compounds have comparable or stronger gastric acid inhibitory activities than that of pantoprazole magnesium. The quantitative structure-activity relationships (QSARs) of the N-aryl isothiourea compounds were also studied by comparative molecular field analysis (CoMFA) computation, and the model structure that was supposed to give more powerful bioactivities was finally predicted. A series of novel N-aryl isothiourea derivatives were synthesized and evaluated for their effects of inhibiting gastric acid secretion using the guinea pig stomach mucous membrane study with pantoprazole magnesium as a positive control. Compounds 2c, 2e, and 2k have higher bioactivity. The quantitative structure-activity relationships also defined these structural requirements.

HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS

Novel compounds having a fused bicyclic heteroaromatic ring system substituted with a thiazole ring are disclosed. The compounds inhibit growth of a variety of types of cancer cells, and are thus useful for treating cancer. Efficacy of these compounds is demonstrated with a system for monitoring cell growth/migration, which shows they are potent inhibitors of growth and/or migration of cancer cells. In addition, compounds of the invention were shown to stop growth of tumors in vivo, and to reduce the size of tumors in vivo. Compositions comprising these compounds, and methods to use these compounds and compositions for treatment of cancers, are disclosed.

HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS

Novel compounds having a fused bicyclic heteroaromatic ring system substituted with a heteroaryl five-membered ring are disclosed. The compounds inhibit growth of a variety of types of cancer cells, and are thus useful for treating cancer. Efficacy of these compounds is demonstrated with a system for monitoring cell growth/migration, which shows they are potent inhibitors of growth and/or migration of cancer cells. In addition, compounds of the invention were shown to stop growth of tumors in vivo, and to reduce the size of tumors in vivo. Compositions comprising these compounds, and methods to use these compounds and compositions for treatment of cancers, are disclosed.

Synthesis and anticonvulsant activity of some substituted 1,2,4-thiadiazoles

A series of new substituted 1,2,4-thiadiazoles were synthesized by appropriate route and screened for anticonvulsant, neurotoxic and sedative-hypnotic activity. The structures of the synthesized compounds were confirmed by IR spectroscopy, 13C NMR and elemental (nitrogen and sulphur) analysis. After i.p. injection of the compounds to mice or rate at doses of 30, 100, and 300 mg/kg, body weights were examined in the maximal electroshock-induced seizures (MES) and subcutaneous pentylenetetrazole (scPTZ)-induced seizure models after 0.5 and 4 h. Rotorod method and phenobarbitone-induced hypnosis potentiation study were employed to examine neurotoxicity and sedative-hypnotic activity, respectively. All the compounds except 4g showed protection against MES screen after 0.5 h. Compounds 3a-c, 4a-c were active at 100 mg/kg dose i.p., whereas remaining compounds showed activity at 300 mg/kg. All 14 compounds except 3 g showed neurotoxicity at 100 and 300 mg/kg after 0.5 h. Compounds 3b and 4b showed NT after 4 h. Two compounds 3b and 4g showed significant (p 0.05) percentage increase in sleeping time i.e. 67% and 59%, respectively. It may be concluded that the synthesized compounds were potent against MES-induced seizures than ScPTZ induced and showed low potency as sedative-hypnotic agent which is advantageous.

Synthesis and anticonvulsant activity of some novel 3-aryl amino/amino-4-aryl-5-imino-Δ2-1,2,4-thiadiazoline

A series of 3-aryl amino/amino-4-aryl-5-imino-Δ2-1,2,4-thiadiazoline have been synthesized using an appropriate synthetic route and characterized by elemental analyses and spectral data. The anticonvulsant activity of all the synthesized compounds was evaluated against maximal electroshock induced seizures (MES) and subcutaneous pentylenetetrazole (ScPTZ) induced seizure models in mice. The neurotoxicity was assessed using the rotorod method. All the test compounds were administered at doses of 30, 100, and 300 mg/kg body weight and the anticonvulsant activity was noted at 0.5 and 4 h time intervals after the drug administration. Some of the compounds were evaluated for the Phenobarbitone induced hypnosis potentiation test. Among the compounds tested, all except 2h showed protection from MES seizures, whereas only 3b was found to be active in the ScPTZ test.